MARKET

XNCR

XNCR

Xencor
NASDAQ
23.82
+0.87
+3.79%
After Hours: 23.79 -0.03 -0.13% 16:55 03/01 EST
OPEN
23.11
PREV CLOSE
22.95
HIGH
23.96
LOW
22.50
VOLUME
817.66K
TURNOVER
0
52 WEEK HIGH
33.38
52 WEEK LOW
16.49
MARKET CAP
1.46B
P/E (TTM)
-11.4299
1D
5D
1M
3M
1Y
5Y
Bad News for Xencor Inc. Stock: This New Risk Has Been Added
TipRanks · 1d ago
Xencor’s Strategic Focus and Pipeline Progress Affirm Buy Rating
TipRanks · 1d ago
Piper Sandler Downgrades Xencor to Neutral, Lowers Price Target to $24
Benzinga · 2d ago
Xencor slips as Piper cuts citing patient death in cancer study
Xencor (XNCR) reports single case of mortality in a mid-stage trial for its prostate cancer antibody. Piper Sandler downgrades Xencor to Neutral from Overweight in reaction to the news. The company has revamped its pipeline and pausing studies in autoimmune disease.
Seeking Alpha · 2d ago
Unveiling 4 Analyst Insights On Xencor
Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company. The average price target for Xencor is $37.5, down 15.41% from the previous average of $44.33. Xencor has four analysts who have provided 12-month price targets for the stock. The company focuses on developing antibodies to treat severe and life-threatening diseases.
Benzinga · 3d ago
RBC Capital Reiterates Outperform on Xencor, Maintains $32 Price Target
Benzinga · 3d ago
BMO Capital Maintains Outperform on Xencor, Lowers Price Target to $34
Benzinga · 3d ago
Wedbush Maintains Outperform on Xencor, Lowers Price Target to $34
Benzinga · 3d ago
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. It uses protein engineering capabilities to enable its understanding of protein structures and interactions and to design technologies and XmAb drug candidates with improved properties. It is advancing its XmAb drug candidates into clinical-stage development. It is focused on the Fc domain, which is part of an antibody that interacts with various segments of the immune system and controls antibody structural architecture. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Vudalimab, XmAb104, XmAb564, XmAb819, XmAb808, Plamotamab, Obexelimab, Sotrovimab, XmAb306/RG6323, and others.

Webull offers Xencor Inc stock information, including NASDAQ: XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.